why choose us

First received: May 03, 2024

Clinical Trial: Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Malaria,Falciparum

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2a Single Centre, Randomised, Placebo-controlled, Double-blind, Dose-escalation, Age De-escalation, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Plasmodium Falcipar

Brief Summary: Mali faces a significant challenge with malaria, particularly among its younger population.While existing measures like seasonal chemoprevention and vaccination have shown efficacy, further innovations are necessary to combat this disease.The monoclonal antibody TB31F shows promise in reducing the transmission of malaria.This clinical trial will evaluate the safety and efficacy of the monoclonal antibody TB31F.

Read more